ArticleEClinicalMedicine2022
Variations in comorbidity burden in people with type 2 diabetes over disease duration: A population-based analysis of real world evidence.
Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Global prevalence of multimorbidity among people living with type 2 diabetes: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Metabolomics in Depression: What We Learn from Preclinical and Clinical Evidences.Molecular neurobiology · 2025Pooled it
- Pooled it
- The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction.Scientific reports · 2024Pooled it
- Perceived Cognitive Function and Glycemic Variability: Baseline Results From a Cognitive Rehabilitation Intervention.The science of diabetes self-management and care · 2024Trial
- Biochemical and Molecular Markers Among Prediabetic and Type 2 Diabetes Mellitus Patients.International journal of endocrinology and metabolism · 2026Article
- Trends in comorbidities and multimorbidity among adults with recently diagnosed diabetes: United States, 1999-2023.Diabetes research and clinical practice · 2026Article
- SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.Diabetes, obesity & metabolism · 2026Observational
- Review
- Osteoarthritis among individuals with diabetes mellitus in Saudi Arabia.Journal of family medicine and primary care · 2026Article
- Associations between impaired awareness of hypoglycaemia and mental health in insulin-treated type 2 and type 1 diabetes in the Hypo-METRICS study.Diabetic medicine : a journal of the British Diabetic Association · 2026Observational
- Prevalence and factors associated with comorbidities in Iranian patients with type 2 diabetes: A national study.PloS one · 2026Article
- Relationships Between Antihypertensive, Glucose- and Lipid-Lowering Medication Adherence, and Demographic and Clinical Characteristics in American Indian Adults With Type 2 Diabetes.Journal of diabetes research · 2026Article
- Associations Between Body Mass Index Trajectories and Healthcare Utilization and Costs Among Patients with Type 2 Diabetes in Finland.Clinical epidemiology · 2026Article
- Mapping sex-based multimorbidity networks in type 1 diabetes: a real-world study from Shanghai.Frontiers in endocrinology · 2026Article
- Regional variation in ambulatory care-sensitive hospitalizations for people with type 2 diabetes in Germany: insights from a claims data analysis using the PopGrouper.Research in health services & regions · 2025Article
- Longitudinal insights into comorbidity patterns and burden among middle-aged and older adults with diabetes in China: a nine-year cohort study using CHARLS.Journal of global health · 2025Article
- The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities.Nature communications · 2025Article
- Association rule mining of time-based patterns in diabetes-related comorbidities on imbalanced data: a pre- and post-diagnosis study.BMC medical informatics and decision making · 2025Article
- Body Mass Index Progression, Development of Complications and Healthcare Costs Over 8 Years in UK Individuals Living With Overweight/Obesity.Advances in therapy · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of type 2 diabetes (T2DM) is increasing, but increasing longevity among persons with diagnosed diabetes may be is associated with more extensive and diverse types of morbidity. The extent and breadth of morbidity and how this varies across sub-groups is unclear and could have important clinical and public health implications. We aimed to estimate comorbidity profiles in people with T2DM and variations across sub-groups and over time. Methods: We identified approximately 224,000 people with T2DM in the Discover-NOW dataset, a real-world primary care database from 2000 to 2020 covering 2.5 million people across North-West London, England, linked to hospital records. We generated a mixed prevalence and incidence study population through repeated annual cross sections, and included a broad set of 35 comorbidities covering traditional T2DM conditions, emerging T2DM conditions and other common conditions.We estimated annual age-standardised prevalence of comorbidities, over the course of the disease in people with T2DM and several sub-groups. Findings: Multimorbidity (two or more chronic conditions) is common in people with T2DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Nearly 30% of T2DM patients had three or more comorbidities at diagnosis, increasing to 60% of patients ten years later. Two of the five commonest comorbidities at diagnosis were traditional T2DM conditions (hypertension (37%) and ischaemic heart disease (10%)) the other three were not (depression (15%), back pain (25%) and osteoarthritis (11%)). The prevalence of each increased during the course of the disease, with more than one in three patients having back pain and one in four having depression ten years post diagnosis.People with five or more comorbidities at diagnosis had higher prevalence of each of the 35 comorbidities. Hypertension (73%) was the commonest comorbidity at diagnosis in this group; followed by back pain (69%), depression (67%), asthma (45%) and osteoarthritis (36%). People with obesity at diagnosis had substantially different comorbidity profiles to those without, and the five commonest comorbidities were 50% more common in this group. Interpretation: Preventative and clinical interventions alongside care pathways for people with T2DM should transition to reflect the diverse set of causes driving persistent morbidity. This would benefit both patients and healthcare systems alike. Funding: The study was funded by the National Institute for Health and Care Excellence (NICE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.